主页
市场
图表与思路
Algo
新闻
Store
经纪商
下载
经济日历
交易信号
网页端
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
IMCR
#1803
Immunocore Holdings plc American Depositary Shares
32.300
0
+2.28%
版块:
基础:
利润货币:
日范围
年范围
日变化
+2.28%
每月变动
-8.00%
6个月变化
-3.52%
年变化
-3.52%
前一天收盘价
31.580
0
Open
32.300
0
Bid
Ask
Low
32.300
0
High
32.300
0
交易量
17
市场
股票
医疗保健
IMCR
Open full chart
Financials
Overview
声明
Statistics
Dividends
Quarterly
Annual
Income statement
Balance sheet
Cash flow
Value
2020
2021
2022
2023
2024
2025
Total assets
—
—
—
597 M
1.01 B
1.07 B
Total liabilities
—
—
—
228.16 M
648.79 M
686.24 M
Total equity
—
—
—
368.84 M
360.72 M
381.03 M
Total liabilities & shareholders' equities
—
—
—
597 M
1.01 B
1.07 B
Total debt
—
—
—
—
—
—
Net debt
—
—
—
—
—
—
Immunocore Holdings plc - American Depositary Shares
Immunocore is a global commercial-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs using soluble T-cell receptor technology.
新闻
Immunocore Holdings plc 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:IMCR) 2026-02-25
Immunocore Holdings plc (IMCR) Q4 2025 Earnings Call Transcript
Immunocore HoldingsQ4每股收益及营收逊于预期
Immunocore Holdings earnings missed by $0.40, revenue fell short of estimates
JAZZ Stock Rises as Q4 Earnings & Sales Top Expectations
RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up
Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y
Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y
Immunocore财报即将公布,黑色素瘤管线取得进展
Immunocore earnings ahead as melanoma pipeline advances
Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down
Immunocore (IMCR) Upgraded to Strong Buy: Here's Why